Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic renal cell cancer?

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 273-277

  Dillman, Robert O ^a   Barth, Neil M ^a   Vandermolen, Louis A ^a   Fong, Warren H ^a   Mahdavi, Khosrow K ^a   McClure, Stephanie E ^a  

^a Hoag Cancer Institute   (United States)

Author keywords

IL 2; long term survival; renal cell cancer

Indexed keywords

INTERLEUKIN 2;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOLOGICAL THERAPY; CANCER SURVIVAL; DRUG MEGADOSE; FEMALE; HOSPITAL PATIENT; HUMAN; KIDNEY CANCER; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREND STUDY;

ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERLEUKIN-2; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79960063707     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2011.0969     Document Type: Article

References (32)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277.
2. Yagoda A, Bab-Rached A-R, Petrylak D. Chemotherapy for advanced renal-cell cancer: 1983-1993. SeminOncol 1995;22:42.
3. Steineck G, Strander H, Carbin BE, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: A randomized trial. Acta Oncol 1990;17:2859.
4. Medical Research Council Renal Cancer Collaborators. Interferon- alpha and survival in metstatic renal carcinoma: early results of a randomised controlled tiral. Lancet 1999;353:14.
5. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2001;20:289.
6. Fyfe GA, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688.
7. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127.
8. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133.
9. Negrier S, Philip T, Stoter G, et al. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 1989;25(suppl3):S21.
10. Weiss GR, Margolin KA, Aronson FR, et al. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol 1992;10:275.
11. Dillman RO. What to do with IL-2? Cancer Biother Radiopharm 1999;14:423.
12. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137.
13. Escudier B, Bellmunt J, Négrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144.
14. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125.
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115.
16. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061.
17. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271.
18. Motzer RJ, Escudier, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet 2008;372:449.
19. Dillman RO, Church C, Oldham RK, et al. Experience with high-dose continuous infusion interleukin-2 in the treatment of 788 cancer patients. Cancer 1993;71:2358.
20. Dillman RO, Wiemann MC, Bury MJ, et al. Hybrid highdose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: A phase II trial of the National Biotherapy Study Group. Cancer Biother Radiopharm 1997;12:5.
21. Dillman RO, Wiemann MC, Tai F, et al. Phase II trial of subcutaneous interferon followed by intravenous hybrid bolus/ continuous infusion interleukin-2 in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 95-09. Cancer Biother Radiopharm 2006;21:130.
22. Soori G, Dillman RO, Wiemann MC, et al. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-a, 5- flouoruracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of Cancer Biotherapy Research Group 94-10. Cancer Biother Radiopharm 2002;17:165.
23. Dillman RO, Church C, Barth NM, et al. Long-term survival after continuous infusion interleukin-2. Cancer Biother Radiopharm 1997;12:243.
24. Negrier S, Maral J, Drevon M, et al. Long-term follow up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe. Cancer J Sci Am 2000;6(supp1):S93.
25. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival updates for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6 (supp11):S55.
26. Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin- 2 for the treatment of metastatic renal cell carcinoma: A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986-2006. Cancer 2008;113:293.
27. Hodi FS, ODay SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711.
28. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411.
29. Wolchok JD, Hoos A, ODay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412.
30. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2- based therapy. J Immunother 2005;28:488.
31. Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib inpatients with metastatic renal cell carcinoma. J Clin Oncol 2008;26:5204.
32. Schwarzberg T, Regan MM, Liu V, et al. Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior anti-angiogenic therapy. J Clin Oncol 2008;26(15S):260s (abstract no. 5044).